DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tropifexor
Tropifexor
Obeticholic Acid and INT-767 Modulate Collagen Deposition in a NASH in Vitro Model Beatrice Anfuso 1, Claudio Tiribelli 1, Luciano Adorini2 & Natalia Rosso 1*
Download
Effect of Non-Alcoholic Fatty Liver Disease (Nafld) on Hepatic Drug Metabolism Enzymes in Human
What Is Non-Alcoholic Steatohepatitis (NASH)?
FXR Signalling: a Novel Target in Metabolic
CRO Service Specialized in NASH-HCC -Proprietary STAMTM Mouse Model
PDF Document
1H. Liver X Receptor-Like Receptors (Version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
EASL 2019 Wrap-Up Metabolic.Pptx
Combination for Therapy Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges
Study Protocol and Results
Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
Synthesis of Novel Farnesoid X Receptor Agonists and Validation Of
12Th International ISSX Meeting 28‒31 July 2019 Portland, Oregon
Bioactive Compound Library Plus (96-Well)
Gut-Pancreas-Liver Axis As a Target for Treatment of NAFLD/NASH
Fxr Agonists Induce Distinct H-12 Structural States
Unless Otherwise Indicated, for Every A61P1/16 (2006.01) A61P9/00 (2006.01) Kind of Regional Protection Available
Top View
FXR Agonists As Therapeutic Options for NAFLD/NASH and Their Clinical Trial Status
( 12 ) Patent Application Publication
Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
CRO Service Specialized in NASH-HCC -Proprietary STAMTM Mouse Model
Bile Acid Homeostasis Paradigm and Its Connotation with Cholestatic Liver Diseases
(51) International Patent Classification: (84) Designated States (Unless
Suffixes Used in the Selection of INN and Their Published INN May 2018
Entwicklung Und Charakterisierung Neuer Farnesoid X Rezeptor-Modulatoren
24October2019 NASH EU Summit Presentation Traber FINAL
Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology
2019 Late-Breaking Abstracts Contents
Fatty Liver Disease (Nafld/Nash)
Farnesoid X Receptor Is an Exciting New Perspective Target for Treatment of Diverse Pathological Disorders: Review
Inventiva's KOL Webcast Event from EASL 2021
Fxr Fxr; Nr1h4
New Drugs for Non‐Alcoholic Steatohepatitis
Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
Pioneering Differentiated Therapies to Treat People with Liver and GI Diseases
Bile Acids in the Pathogenesis and Treatment of NASH
Bile Acids Mediated Potential Functional Interaction Between FXR